ARTICLE | Company News
Agios, Foundation Medicine deal
April 15, 2013 7:00 AM UTC
The companies partnered to develop and potentially commercialize a diagnostic to identify which cancer patients are most likely to respond to Agios' isocitrate dehydrogenase 1 (IDH1) and IDH2 inhibi...